Quick Summary:
In the rapidly evolving healthcare industry, staying ahead of market trends is crucial to maintaining competitive advantage. Gain an unparalleled edge over competition with our comprehensive report on the Global Pulmonary / Respiratory Drug Delivery Market, projected to reach a sizeable $77.7 billion by 2030. This report offers extensive analysis of the market, factoring in the ongoing post pandemic recovery and the trends influencing significant segments such as Metered Dose and Dry Powder Inhalers.
Delve deeper into the market trends with a granular look at various influential territories including the U.S and China, poised for remarkable growth. Catch up with the competition with our carefully curated list of market players including major firms such as AireHealth, Channel Products and Micot. Our report also includes special features such as market presence across multiple geographies, access to digital archives and bespoke updates to keep you abreast of any developments in the market. Make an informed investment in market intelligence and future-proof your business with our expertly crafted, meticulously researched report.
Global Pulmonary / Respiratory Drug Delivery Market to Reach $77.7 Billion by 2030
The global market for Pulmonary / Respiratory Drug Delivery estimated at US$53.3 Billion in the year 2022, is projected to reach a revised size of US$77.7 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2022-2030. Metered Dose Inhalers, one of the segments analyzed in the report, is projected to record 4.4% CAGR and reach US$32.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Dry Powder Inhalers segment is readjusted to a revised 5.5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $15.8 Billion, While China is Forecast to Grow at 4.5% CAGR
The Pulmonary / Respiratory Drug Delivery market in the U.S. is estimated at US$15.8 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$13.6 Billion by the year 2030 trailing a CAGR of 4.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.Select Competitors (Total 42 Featured) -
- AireHealth, LLC
- Allergenix
- Channel Products
- Chemring Group PLC
- Epalex Corp.
- Genetic SpA
- Micot
- Omron Healthcare India
- Pneuma Respiratory
- Rotech Healthcare, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Frequently Asked Questions about the Global Market for Pulmonary / Respiratory Drug Delivery
What is the estimated value of the Global Market for Pulmonary / Respiratory Drug Delivery?
The Global Market for Pulmonary / Respiratory Drug Delivery was estimated to be valued at $53.3 Billion in 2022.
What is the growth rate of the Global Market for Pulmonary / Respiratory Drug Delivery?
The growth rate of the Global Market for Pulmonary / Respiratory Drug Delivery is 4.8%, with an estimated value of $77.7 Billion by 2030.
What is the forecasted size of the Global Market for Pulmonary / Respiratory Drug Delivery?
The Global Market for Pulmonary / Respiratory Drug Delivery is estimated to be worth $77.7 Billion by 2030.
Who are the key companies in the Global Market for Pulmonary / Respiratory Drug Delivery?
Key companies in the Global Market for Pulmonary / Respiratory Drug Delivery include AireHealth, LLC, Allergenix, Channel Products, Chemring Group PLC, Epalex Corp., Genetic SpA, Micot, Omron Healthcare India, Pneuma Respiratory and Rotech Healthcare, Inc..
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | October 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 53.3 Billion |
| Forecasted Market Value ( USD | $ 77.7 Billion |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Pulmonary/ Respiratory Drug Delivery - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Asthma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Cystic Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 10: World Pulmonary / Respiratory Drug Delivery Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 11: World Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 12: World Historic Review for Pulmonary / Respiratory Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 13: World 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Metered Dose Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 15: World Historic Review for Metered Dose Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 16: World 16-Year Perspective for Metered Dose Inhalers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Dry Powder Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for Dry Powder Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for Dry Powder Inhalers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Nebulizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 21: World Historic Review for Nebulizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 22: World 16-Year Perspective for Nebulizers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 23: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 24: World Historic Review for Chronic Obstructive Pulmonary Disease (COPD) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 25: World 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 26: USA Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 27: USA Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: USA 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 29: USA Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: USA Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: USA 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- CANADA
- Table 32: Canada Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: Canada Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: Canada 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 35: Canada Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Canada Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: Canada 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- JAPAN
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 38: Japan Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Japan Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: Japan 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 41: Japan Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Japan Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Japan 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- CHINA
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 44: China Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: China Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: China 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 47: China Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: China Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: China 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- EUROPE
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 50: Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- FRANCE
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 59: France Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: France Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: France 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 62: France Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: France Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: France 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- GERMANY
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 65: Germany Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: Germany Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: Germany 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 68: Germany Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Germany Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: Germany 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- ITALY
- Table 71: Italy Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Italy Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: Italy 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 74: Italy Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Italy Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: Italy 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 77: UK Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: UK Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: UK 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 80: UK Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: UK Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: UK 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 83: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: Rest of Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: Rest of Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 86: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Rest of Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: Rest of Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 89: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Asia-Pacific Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: Asia-Pacific 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Asia-Pacific Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 94: Asia-Pacific 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- REST OF WORLD
- Table 95: Rest of World Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Rest of World Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 97: Rest of World 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 98: Rest of World Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Rest of World Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 100: Rest of World 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
Companies Mentioned
A selection of companies mentioned in this report includes:
- AireHealth, LLC
- Allergenix
- Channel Products
- Chemring Group PLC
- Epalex Corp.
- Genetic SpA
- Micot
- Omron Healthcare India
- Pneuma Respiratory
- Rotech Healthcare, Inc.
